Last checked at 27 Apr 2023 07:00
27 April 2023
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Block Listing Six Monthly Return
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of applicant: | Avacta Group plc | |||
Name of scheme: | EMI scheme | |||
Period of return: | From: | 28 October 2022 | 27 April 2023 | |
Balance of unallotted securities under scheme(s) from previous return: | 459,500 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 800,000 | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 845,322 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 414,178 | |||
Name of applicant: | Avacta Group plc | |||
Name of scheme: | LTIP scheme | |||
Period of return: | From: | 28 October 2022 | 27 April 2023 | |
Balance of unallotted securities under scheme(s): | 459,187 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 2,200,000 | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 288,598 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,370,589 | |||
Name of contact: | Tony Gardiner, Company Secretary |
Telephone number of contact: | + 44 (0) 1904 217070 |
Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer Michael Vinegrad, Group Communications Director
| Tel: +44 (0) 1904 21 7070 www.avacta.com |
Stifel Nicolaus Europe Limited (Nomad and Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown
| Tel: +44 (0) 207 710 7600 www.stifel.com |
FTI Consulting (Financial Media and IR) Simon Conway / Alex Shaw / George Kendrick
| Tel: +44(0) 203 727 1000 Avacta.LS@fticonsulting.com |
Zyme Communications (Trade and Regional Media) Lily Jeffery
| Tel: +44 (0)7891 477 378 lily.jeffery@zymecommunications.com |
About Avacta Group plc - https://www.avacta.com
Avacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.
Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in patients with locally advanced or metastatic selected solid tumours.
The Affimer® platform is an alternative to antibodies that has been designed to address many of the drawbacks of antibodies which, despite their shortcomings, currently dominate the immuno-diagnostics and immuno-therapeutics markets.
The pre|CISION™ tumour targeting platform can be used to modify a chemotherapy in order to selectively release the active drug in tumour tissue thereby reducing the systemic exposure that causes damage to healthy tissues. pre|CISION™ modified chemotherapies are designed to reduce the side effects and improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.
Avacta's Diagnostics Division develops and supplies a broad range of in-vitro diagnostic (IVD) solutions. The Division is growing rapidly through an M&A strategy to deliver a global scale IVD business providing market leading solutions for healthcare professionals and consumers to inform treatment and monitor health and well-being. In October 2022, Avacta acquired Launch Diagnostics which serves the hospital pathology laboratory market in the UK and Europe. Avacta Diagnostic's research and development centre in Wetherby, UK uses its proprietary Affimer® platform to differentiate immunodiagnostic products to provide marketing leading performance.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts